GRAIL (NASDAQ: GRAL) is a small-cap biotechnology company that has gone on a very strong run over the last month and a half. Shares of the healthcare stock are up 58% since Oct. 24, as of the Dec. 11 close. The company has interesting technology that sets it apart from many small biotechs. I'll explain what this firm does, its uniqueness, and my view on this stock that targets a $100 billion market.
